TPA Global offers a look on this evolving landscape and will guide you through with its Tax Technology roadmap. Find out what your technological needs really are and arm yourself for the digital future. Watch the introduction video by clicking on the download button.

The requirements for full disclosure after BEPS are affecting multinational corporations in one way or the other. In this world of complete transparency, one aspect of being fully in control is getting a strong grip on your intercompany costs. In our discussions with CFOs over multiple projects, they have stressed on the need for a ‘lean and mean’ finance set-up that allows to achieve the following objectives in terms of intercompany service costs:

The world of taxation is changing. The release of BEPS, although driven by a tax motive, has wide ranging implications for a CFO as it not only demands full transparency on tax sensitive data but also requires a full disclosure of the operational and governance model of the company, in order to check for misalignments between all three.

Because of this, it is more crucial than ever that CFOs step out of their comfort zone and begin their journey from ‘’staying out of trouble’’ towards being ‘’fully in control’’ of business operations, to avoid controversies and consequential reputational and personal risks.

https://www.tpa-global.com/cforoadmap

Providing the solution to collect the required CbC data fully automated.

• Understand the concept underlying the UK diverted profit tax;
• Be able to make an initial assessment as to whether your UK activities have a risk of falling within scope of the UK diverted profit tax regulations;
• Understand your notification and reporting obligations; and
• Be clear of the timeframe within which you have to take action.

• Address a practical way to source & automate Country by Country data collection
• Provide all participants with a Country by Country instruction manual
• Provide solutions on how to complete the 2 tables requested by the tax authorities
• Provide disclosure options to be discussed with your CFO
• Run a list of FAQ per category of stakeholders

Should the MNE's in the pharmaceutical industry resort to in-license R&D from specialty shops and universities?

What are the major business, transfer pricing and valuation aspects of 'patent cliffs' in the industry?

Creating value for your company through active intangibles management.